Clinical trial
A Single-Center, Randomized, Open-Label, Two-Period, Two-Sequence, Single-Dose, Crossover Bioequivalence Study of Methylcobalamin Injection and Methylcobalamin for Injection in Healthy Subjects Under Fasting Conditions
NCT07281872 is registered in ClinicalTrials.gov with Wanbangde Pharmaceutical Group Co., LTD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-Center, Randomized, Open-Label, Two-Period, Two-Sequence, Single-Dose, Crossover Bioequivalence Study of Methylcobalamin Injection and Methylcobalamin for Injection in Healthy Subjects Under Fasting Conditions
- Lead sponsor
- Wanbangde Pharmaceutical Group Co., LTD
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 29, 2025
- Completion date
- November 21, 2025
- Enrollment
- 20 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
therapeutic equivalency, healthy